Tradestie Institutional Equity Comparison Engine
CING vs ANRO โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
ANRO Overall Edge
ANRO Captures Institutional Edge (2โ1 Pillars ยท 4โ1 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Alto Neuroscience Inc. (ANRO) driven by superior Growth & Margin, Momentum & Technical while CING counters with relative strength in Options & Structure. Fundamentally, CING trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus ANRO at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, CING sits in BREAKDOWN (16th %ile IV; Dealer Gamma Walls on Pro) against ANRO sits in BREAKDOWN (8th %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
Tie
CING N/M vs ANRO N/M Fwd P/E
Growth & Margin Winner
ANRO
Op Margin 0.0% vs 0.0% ยท YoY +0.0% vs +0.0%
Momentum & Technical Winner
ANRO
1Y +36.4% vs +107.3% ยท 52W Pos 18% vs 54%
Options & Structure Winner
CING
BREAKDOWN (16th %ile IV) vs BREAKDOWN (8th %ile IV)
CING
NASDAQ
Cingulate Inc. Common Stock
Pharmaceutical Preparations
$4.76
+26.93% 1D
Market Cap
$62.5M
1M Return
+9.17%
1Y Return
+36.39%
Forward P/E
N/M
Unified AI Score
44.8 / 100
HOLD
Tech 31.0
Fund 50.0
Flow 67.0
Mom 60.0
ANRO
NYSE
Alto Neuroscience Inc.
Pharmaceutical Preparations
$25.11
-7.41% 1D
Market Cap
$1.2B
1M Return
+10.04%
1Y Return
+107.35%
Forward P/E
N/M
Unified AI Score
34.3 / 100
SELL
Tech 15.0
Fund 38.0
Flow 64.0
Mom 40.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
CING +36.39%
ANRO +107.35%
Spread: +70.96 pp (ANRO Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
CING TTM Op. Margin: 0.0%
ANRO TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CING vs ANRO. Trailing 12-month operating profitability (CING 0.0% vs ANRO 0.0%) and valuation multiples (CING N/M vs ANRO N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | CING | ANRO | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $62.5M | $1.2B | Larger Scale | ANRO |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | +0.0% | +0.0% | Higher Growth | Tie |
| Operating Margin (TTM) Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Net Profit Margin Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Return on Equity (ROE) Capital Efficiency | -198.7% | -46.7% | Higher ROE | ANRO |
| 52-Week Range Position Momentum | 18% ($3โ$12) | 54% ($11โ$37) | Stronger Trend | ANRO |
| Beta / 30D Volatility Risk Regime | 1.13ฮฒ ยท 117% Vol | 2.02ฮฒ ยท 93% Vol | Lower Realized Risk | ANRO |
| Unified Institutional Score Composite Signal | 44.8 / 100 (HOLD) | 34.3 / 100 (SELL) | Higher Composite | CING |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full CING vs ANRO Buy Guide
CING
BREAKDOWN
170d in phase ยท OBV ACCUMULATION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
16th %ile
IV Regime
Compressed (<25th %ile)
ANRO
BREAKDOWN
58d in phase ยท OBV ACCUMULATION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
8th %ile
IV Regime
Compressed (<25th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither CING nor ANRO registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.